Scientific Knowledge on the Subject: Observational studies have shown associations between low 25-hydroxyvitamin D levels and increased mortality among critically ill patients. Administration of vitamin D and its metabolites has potent immunomodulatory effects in vitro but has not been evaluated in vivo.
Introduction
Sepsis is common among critically ill patients and associated with considerable morbidity and mortality (1) . Observational studies among critically ill patients, many of whom have sepsis, have shown strong associations between decreased 25-hydroxyvitamin D (25D) levels and adverse outcomes, including increased length of stay (2) , infection (3), acute kidney injury (AKI) (4) , and mortality (2) (3) (4) . Additionally, studies from our group have documented an inverse association between 25D levels and severity of sepsis (5, 6) .
Whether these associations are causal in nature is unknown; however, a biologically plausible role for vitamin D in sepsis is suggested by the important effects of its active metabolite, 1,25-dihydroxyvitamin D (1,25D), on host defense (7). 1,25D enhances innate immunity primarily by signaling monocytes, macrophages, and epithelial cells to increase production of cathelicidins, a major family of antimicrobial peptides (8) .
Cathelicidins constitute an important component of immunologic defense and have activity against gram-positive (9-11) and gram-negative bacteria (12, 13) as well as some viruses and fungi (14, 15) . In animal models, deficiency of cathelicidin is associated with increased susceptibility to bacterial infection (9, 10, 12) , whereas overexpression confers protection (13) . Among patients undergoing dialysis, plasma levels of the only known human cathelicidin antimicrobial peptide (hCAP-18) are directly associated with 1,25D plasma levels and inversely associated with 1-year infectionrelated mortality (16) .
Calcitriol RCT 4 In addition to its important effects of innate immunity, 1,25D inhibits production of proinflammatory cytokines produced by T helper cells including interleukin (IL)-2, IL-6, IL-8, and tumor necrosis factor-α (TNFα) (17, 18) , increases production of anti-inflammatory cytokines such as 20) , and may attenuate AKI (21, 22) , an important complication of sepsis. Most of these studies, however, were performed in vitro or in animal models or were observational in nature.
We performed a double-blind, randomized, placebo-controlled, physiologic study among critically ill patients with sepsis to test whether 1,25D (calcitriol) administration has beneficial effects on markers of immunity, inflammation, and kidney injury. We hypothesized that calcitriol would increase markers of innate immunity (hCAP-18), decrease markers of inflammation (IL-6), and decrease markers of kidney injury [neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1)].
Methods

Study Design
We conducted a double-blind, randomized physiologic study of calcitriol vs. placebo among patients admitted to intensive care units (ICUs) at Brigham and Women's Hospital (BWH) and Beth Israel Deaconess Medical Center (both in Boston, MA).
Patients or their surrogates provided written informed consent and all protocols were approved by the Institutional Review Boards of the respective hospitals.
Study Treatments and Sample Collections
Patients were randomly assigned to receive, in 1:1 fashion, a single intravenous dose of calcitriol 2µg or an identically appearing equal volume of saline (2mL). We chose 2µg for the dose of calcitriol based on multiple randomized controlled trials of calcitriol in patients with chronic kidney disease in which this dose was shown to be well tolerated (minimal changes in serum calcium or phosphate) and effective at reducing parathyroid hormone levels (26, 27) . Additionally, in the only pilot study that evaluated calcitriol among critically-ill patients, a dose of 2µg was used and no adverse effects were reported (28).
We collected plasma and urine samples at four time points: time 0 (immediately prior to study drug administration) and 6, 24, and 48 hours later. We stored plasma and urine aliquots at -80ºC within 1 hour of collection. Additionally, whole blood leukocyte RNA was collected at time 0 and 24 hours later using Tempus blood RNA tubes containing stabilizing reagent which inactivates cellular RNases (Applied Biosystems/Life Technologies; Grand Island, NY).
Outcomes
The primary outcome was plasma hCAP-18 protein levels assessed at 24 hours. Prespecified secondary outcomes included change in leukocyte mRNA expression of hCAP-18, IL-6, IL-10, and TNF-α, assessed at 0 and 24 hours, as well as plasma cytokine levels (IL-6, IL-10, TNF-α, IL-1β, and IL-2) and urinary kidney injury markers Plasma protein levels. hCAP-18 protein levels were measured at all four time points in singulate using a commercial ELISA kit (Hycult Biotech; Netherlands). Plasma cytokine levels were measured at all four time points in duplicate using a bead-based multiplex assay (Millipore; Billerica, MA). Vitamin D metabolites were measured in singulate at time 0 and 6 hours later using immunoaffinity enrichment and liquid chromatographytandem mass spectrometry.
Urinary kidney injury markers. Urinary NGAL and KIM-1 levels were measured in duplicate at all four time points using a microbead-based sandwich ELISA, and were normalized to urinary creatinine concentrations to account for the influence of urinary dilution on biomarker concentrations.
Additional assay characteristics, including coefficients of variation, are provided in Table   E1 in the online supplement.
Clinical Data
Although the study was not powered to detect a difference in clinical outcomes, the following data were recorded on all patients: ICU-, hospital-, and 28-day mortality; ICUand hospital length of stay; duration of mechanical ventilation; Sequential Organ Failure Assessment (Cardiovascular) score at 0, 24, and 48 hours after study drug administration; urine output; and new RRT requirement. To avoid the confounding effect of mortality, we assessed ICU-and hospital length of stay only among survivors.
We also calculated ventilator-free days, defined as 28 minus the number of ventilatordependent days, assuming survival to 28 days or discharge from the hospital. Patients who died before 28 days were assigned a score of zero (29) . Investigator D.E.L. adjudicated all outcomes by reviewing electronic medical records, and was blinded to treatment assignment and biomarker results at the time of adjudication.
Statistical Analysis
We determined that a sample of 60 patients would provide the study with 80% power to detect a relative increase of 50% in plasma hCAP-18 protein levels, with a two-sided alpha of 5%. We therefore enrolled 67 patients to account for missing data. All Calcitriol RCT 10
Effect of calcitriol on vitamin D metabolites
We found significantly increased plasma 1,25D levels at 6 hours in calcitriol vs. placebotreated patients [75.7 (52.1-115.5) and 16.9 (9.0-26.9) pg/ml, p<0.001, Fig 2] . Levels of other vitamin D metabolites were unchanged and are shown in Table E2 in the online supplement.
Effect of calcitriol on plasma protein levels
We found similar plasma hCAP-18 protein levels ( 
Effect of calcitriol on mRNA expression
We found significantly increased hCAP-18 mRNA expression at 24 hours in calcitriol vs.
placebo-treated patients [1.8 (0.9-3.3) and 1.0 (0.7-1.8) fold-elevation from baseline, p=0.04, Fig 4A] . Additionally, we found a graded relationship between fold-elevation in 1,25D and fold-elevation in hCAP-18 mRNA expression (p for trend 0.003, Fig 4B) .
Patients who received calcitriol also had higher IL-10 mRNA expression at 24 hours compared to patients who received placebo (Fig 4A) . Similar to hCAP-18, we found a graded relationship between fold-elevation in 1,25D and fold-elevation in IL-10 mRNA expression (p for trend 0.004, Fig E1A in the online supplement) . In contrast, we found no significant between-group differences in mRNA expression of IL-6, TNF-α, MKP-1, I K Bα, or TLR4 (Fig 4A and Fig E1B in the online supplement) .
Effect of calcitriol on urinary kidney injury biomarkers
We found similar urinary levels of KIM-1 and NGAL in calcitriol vs. placebo-treated patients at all four time points (Fig 5) .
Clinical and safety outcomes
Patients who received calcitriol vs. placebo had similar mortality, ICU-and hospital length of stay, Sequential Organ Failure Assessment (Cardiovascular) score at 24 and 48 hours, and other clinical and physiologic outcomes (Table 3) . No patients developed hypercalcemia within 48 hours of study drug administration, and the incidence of hyperphosphatemia was rare and similar between groups (Table 3) . Calcium, phosphate, creatinine, and white blood-cell count values at times 0, 24, and 48 hours are shown in Table E3 in the online supplement.
Discussion
In this doubled blind, randomized, placebo-controlled physiologic study we report that calcitriol administered to critically ill patients with sepsis did not increase plasma hCAP-18 protein levels at 24 hours. Additionally, we report that calcitriol-vs. placebo-treated patients had higher leukocyte mRNA expression of both hCAP-18 and the antiinflammatory cytokine, IL-10, at 24 hours. Finally, patients treated with calcitriol vs. placebo had similar plasma cytokine (IL-6, TNF-α, and others) and urinary kidney injury marker levels (KIM-1 and NGAL). protein levels. Consistent with this notion, others have shown an absence of correlation between leukocyte hCAP-18 mRNA expression and plasma protein levels (49) . Finally, although not statistically significant, patients in the placebo group had a higher WBC count and higher hCAP-18 protein levels at baseline than patients in the calcitriol group.
We found increased IL-10 mRNA expression in calcitriol vs. placebo-treated patients but did not detect significant differences in mRNA expression or protein levels of other inflammatory markers, including IL-6 and TNF-α. These findings differ from previous in vitro studies, in which 1,25D supplementation decreases pro-inflammatory cytokines (17, 18) . Previous in vivo findings, in contrast, have been mixed, with studies finding that nutritional vitamin D decreases (18, 50) , increases (51), and produces no change (52, 53) in pro-inflammatory cytokines levels. In the current study, it is likely that the heterogenous and rapidly evolving nature of sepsis and critical illness created substantial "noise" and diminished our ability to detect an effect of calcitriol on inflammatory markers.
We acknowledge the limitations of this study including modest sample size and single dose administration of calcitriol. Although 1,25D levels increased ~5-fold in patients treated with calcitriol, the plasma levels achieved were nonetheless lower than concentrations required to produce immune responses in most in vitro studies. Thus, it is possible that higher doses of calcitriol would have produced a greater effect on the biomarkers that were studied. We did not measure levels of vitamin D metabolites at 24 and 48 hours, which might have yielded pharmacokinetic data that could have been informative for future studies. We did not measure all potentially relevant markers of mineral metabolism such as vitamin D binding protein (VDBP), parathyroid hormone, and FGF23. We measured total leukocyte mRNA expression but did not isolate cellspecific populations such as monocytes. Finally, because of the large number of tests performed, we acknowledge the possibility of a type I error among the secondary endpoints .
In conclusion, our central findings are that administration of a single dose of 1,25D to critically ill patients with sepsis failed to increase plasma hCAP-18 protein levels but (31) 9 (25) 3 (8) 7 (19) 2 (6) 5 (14) 19 (61) 7 (23) 6 (19) 2 (6) 3 ( (47) 19 (61) 12 ( (44) 13 (36) 3 (8) 21 (15-24) 1 (0-3) 22 (71) 14 (45) 13 (42) 5 ( (14) 31 (86) 4 (11) 5 (14) 19 (61) Table 1 . Baseline Demographic and Clinical Characteristics. IQR=Interquartile Range; COPD=Chronic Obstructive Pulmonary Disease; *APACHE II=Acute Physiology and Chronic Health Evaluation II, an ICU severity of illness scoring system ranging from 0 to 71, with higher scores corresponding to more severe disease; †SOFA-CV=Sequential Organ Failure Assessment (Cardiovascular), an ICU severity of illness scoring system ranging from 0 to 4, with higher scores corresponding to more severe hypotension and greater vasopressor requirements; ‡AKI=Acute Kidney Injury, defined in the methods; RRT=Renal Replacement Therapy; §Glucocorticoids included hydrocortisone and prednisone; ǁAntiepileptic agents included levetiracetam, phenytoin, valproic acid, and topiramate. Table E1 . Assay characteristics. LCMS=Liquid chromatography-tandem mass spectrometry; CV=Coefficient of variation (calculated from blinded split samples).
*
The assay recognizes the 37 amino acid biologically active C-terminal fragment, LL-37, which is cleaved from hCAP-18. † We assigned half the lower limit of detection to plasma samples with undetectable IL-1β or IL-2 protein levels. No other analytes had undetectable levels. 
